| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 59 | 2025 | 669 | 7.280 |
Why?
|
| Depressive Disorder | 12 | 2017 | 451 | 2.160 |
Why?
|
| Cognition Disorders | 9 | 2022 | 554 | 1.530 |
Why?
|
| Anxiety Disorders | 10 | 2017 | 677 | 1.470 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2025 | 624 | 1.250 |
Why?
|
| Depression | 18 | 2020 | 1225 | 1.050 |
Why?
|
| Psychiatric Status Rating Scales | 15 | 2018 | 804 | 1.030 |
Why?
|
| REM Sleep Behavior Disorder | 2 | 2025 | 16 | 1.010 |
Why?
|
| Anxiety | 13 | 2019 | 956 | 0.940 |
Why?
|
| Mental Disorders | 7 | 2016 | 827 | 0.910 |
Why?
|
| Aggression | 1 | 2024 | 226 | 0.780 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 253 | 0.680 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 177 | 0.650 |
Why?
|
| Dementia | 4 | 2014 | 448 | 0.650 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 222 | 0.620 |
Why?
|
| Dystonia | 2 | 2020 | 171 | 0.530 |
Why?
|
| Psychotic Disorders | 4 | 2019 | 140 | 0.520 |
Why?
|
| Veterans | 6 | 2025 | 1726 | 0.510 |
Why?
|
| Aged | 37 | 2025 | 19072 | 0.480 |
Why?
|
| Comorbidity | 11 | 2020 | 1498 | 0.470 |
Why?
|
| Surveys and Questionnaires | 11 | 2018 | 3662 | 0.460 |
Why?
|
| Middle Aged | 41 | 2025 | 25980 | 0.460 |
Why?
|
| Depressive Disorder, Major | 3 | 2020 | 401 | 0.450 |
Why?
|
| Humans | 77 | 2025 | 123180 | 0.450 |
Why?
|
| Panic Disorder | 2 | 2011 | 45 | 0.440 |
Why?
|
| Torticollis | 3 | 2021 | 71 | 0.430 |
Why?
|
| Delusions | 2 | 2012 | 17 | 0.420 |
Why?
|
| Hallucinations | 2 | 2012 | 26 | 0.410 |
Why?
|
| Health Services | 1 | 2012 | 71 | 0.410 |
Why?
|
| Health Status | 2 | 2012 | 374 | 0.400 |
Why?
|
| Illusions | 1 | 2012 | 8 | 0.400 |
Why?
|
| Drug Utilization | 1 | 2013 | 158 | 0.390 |
Why?
|
| Disclosure | 1 | 2013 | 155 | 0.390 |
Why?
|
| Multiple Sclerosis | 1 | 2015 | 335 | 0.380 |
Why?
|
| Family Health | 3 | 2011 | 259 | 0.380 |
Why?
|
| Nootropic Agents | 2 | 2009 | 25 | 0.380 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 32 | 0.360 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2014 | 353 | 0.360 |
Why?
|
| Aged, 80 and over | 17 | 2020 | 6372 | 0.350 |
Why?
|
| Male | 47 | 2025 | 60022 | 0.340 |
Why?
|
| Antiparkinson Agents | 2 | 2009 | 65 | 0.330 |
Why?
|
| Propylamines | 1 | 2009 | 8 | 0.320 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2009 | 27 | 0.320 |
Why?
|
| Prevalence | 11 | 2020 | 2405 | 0.320 |
Why?
|
| Dystonic Disorders | 2 | 2021 | 83 | 0.300 |
Why?
|
| Female | 44 | 2025 | 65428 | 0.290 |
Why?
|
| Severity of Illness Index | 13 | 2018 | 2838 | 0.280 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2006 | 90 | 0.270 |
Why?
|
| Physical Therapy Modalities | 1 | 2006 | 50 | 0.260 |
Why?
|
| Psychometrics | 6 | 2013 | 667 | 0.250 |
Why?
|
| Prodromal Symptoms | 1 | 2025 | 9 | 0.240 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2020 | 202 | 0.240 |
Why?
|
| Alcohol Amnestic Disorder | 1 | 2003 | 2 | 0.230 |
Why?
|
| Polysomnography | 1 | 2025 | 137 | 0.220 |
Why?
|
| Patient Health Questionnaire | 2 | 2020 | 16 | 0.220 |
Why?
|
| Indans | 1 | 2004 | 53 | 0.220 |
Why?
|
| Violence | 1 | 2024 | 114 | 0.210 |
Why?
|
| HIV Infections | 1 | 2015 | 1868 | 0.210 |
Why?
|
| Cross-Sectional Studies | 11 | 2020 | 3377 | 0.210 |
Why?
|
| Mental Health Services | 3 | 2015 | 246 | 0.210 |
Why?
|
| Psychotropic Drugs | 3 | 2011 | 125 | 0.210 |
Why?
|
| Adult | 23 | 2025 | 29039 | 0.200 |
Why?
|
| Piperidines | 1 | 2004 | 198 | 0.200 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2016 | 650 | 0.200 |
Why?
|
| Alzheimer Disease | 4 | 2015 | 766 | 0.200 |
Why?
|
| Neuropsychological Tests | 7 | 2013 | 921 | 0.190 |
Why?
|
| Pilot Projects | 5 | 2025 | 1387 | 0.180 |
Why?
|
| Neoplasms | 1 | 2015 | 2766 | 0.180 |
Why?
|
| Internationality | 1 | 2020 | 130 | 0.170 |
Why?
|
| Parasomnias | 1 | 2019 | 4 | 0.170 |
Why?
|
| Unconsciousness | 1 | 2019 | 17 | 0.170 |
Why?
|
| Combat Disorders | 1 | 2019 | 22 | 0.170 |
Why?
|
| Dreams | 1 | 2019 | 24 | 0.170 |
Why?
|
| Tremor | 1 | 2020 | 129 | 0.160 |
Why?
|
| Fatigue | 3 | 2010 | 217 | 0.160 |
Why?
|
| Activities of Daily Living | 3 | 2015 | 404 | 0.160 |
Why?
|
| Sleep | 1 | 2021 | 348 | 0.150 |
Why?
|
| Evaluation Studies as Topic | 2 | 2008 | 258 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 711 | 0.150 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 94 | 0.150 |
Why?
|
| Hippocampus | 1 | 2003 | 812 | 0.150 |
Why?
|
| Interview, Psychological | 1 | 2018 | 99 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 122 | 0.140 |
Why?
|
| Phenotype | 3 | 2021 | 4224 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2019 | 225 | 0.140 |
Why?
|
| Public Housing | 1 | 2016 | 7 | 0.130 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 458 | 0.130 |
Why?
|
| Age of Onset | 6 | 2014 | 581 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 3098 | 0.130 |
Why?
|
| Psychiatry | 1 | 2019 | 263 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 161 | 0.130 |
Why?
|
| Apathy | 1 | 2015 | 9 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 367 | 0.120 |
Why?
|
| Suicidal Ideation | 1 | 2018 | 214 | 0.120 |
Why?
|
| Mass Screening | 1 | 2020 | 790 | 0.120 |
Why?
|
| Epilepsy | 1 | 2002 | 859 | 0.120 |
Why?
|
| Motor Skills Disorders | 2 | 2014 | 9 | 0.110 |
Why?
|
| Disabled Persons | 1 | 2015 | 100 | 0.110 |
Why?
|
| Heterozygote | 3 | 2014 | 672 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2016 | 1011 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 219 | 0.110 |
Why?
|
| ROC Curve | 2 | 2020 | 557 | 0.110 |
Why?
|
| Research Design | 2 | 2015 | 688 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 365 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2011 | 1245 | 0.110 |
Why?
|
| Mental Health | 2 | 2014 | 348 | 0.110 |
Why?
|
| Role | 1 | 2013 | 26 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 1088 | 0.100 |
Why?
|
| Movement | 1 | 2014 | 167 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 225 | 0.100 |
Why?
|
| Schizophrenia | 1 | 2015 | 300 | 0.100 |
Why?
|
| Mutation | 4 | 2010 | 5774 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 1872 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2013 | 180 | 0.100 |
Why?
|
| Convergence, Ocular | 1 | 2011 | 2 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 2011 | 28 | 0.100 |
Why?
|
| Independent Living | 1 | 2012 | 65 | 0.090 |
Why?
|
| Memory Disorders | 2 | 2004 | 235 | 0.090 |
Why?
|
| Ocular Motility Disorders | 1 | 2011 | 38 | 0.090 |
Why?
|
| Behavior Therapy | 1 | 2013 | 256 | 0.090 |
Why?
|
| Point Mutation | 2 | 2010 | 348 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2013 | 287 | 0.090 |
Why?
|
| Oculomotor Muscles | 1 | 2011 | 64 | 0.090 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2010 | 28 | 0.090 |
Why?
|
| Database Management Systems | 1 | 2010 | 31 | 0.090 |
Why?
|
| Societies, Scientific | 1 | 2010 | 26 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 475 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 3 | 2005 | 1117 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2010 | 71 | 0.090 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 66 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 640 | 0.090 |
Why?
|
| Glucosylceramidase | 1 | 2010 | 27 | 0.090 |
Why?
|
| United States | 6 | 2019 | 10618 | 0.090 |
Why?
|
| alpha-Synuclein | 3 | 2005 | 114 | 0.090 |
Why?
|
| Quality of Life | 5 | 2021 | 1932 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 606 | 0.080 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2009 | 15 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1069 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2015 | 753 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 197 | 0.080 |
Why?
|
| Genetic Counseling | 1 | 2010 | 225 | 0.080 |
Why?
|
| Psychological Tests | 1 | 2009 | 92 | 0.080 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 7 | 0.080 |
Why?
|
| Substantia Nigra | 1 | 2008 | 33 | 0.080 |
Why?
|
| Health Planning Guidelines | 1 | 2008 | 32 | 0.080 |
Why?
|
| Lewy Body Disease | 2 | 2004 | 18 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 564 | 0.070 |
Why?
|
| Movement Disorders | 1 | 2010 | 221 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2009 | 181 | 0.070 |
Why?
|
| Stroke | 1 | 2014 | 958 | 0.070 |
Why?
|
| Education | 1 | 2007 | 105 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2020 | 4709 | 0.070 |
Why?
|
| Young Adult | 5 | 2020 | 8870 | 0.070 |
Why?
|
| MEDLINE | 1 | 2006 | 20 | 0.070 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 11 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2016 | 12103 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2020 | 1169 | 0.070 |
Why?
|
| Motivation | 1 | 2008 | 314 | 0.070 |
Why?
|
| Deep Brain Stimulation | 1 | 2011 | 397 | 0.070 |
Why?
|
| Emotions | 1 | 2008 | 364 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2006 | 94 | 0.060 |
Why?
|
| Bipolar Disorder | 1 | 2009 | 347 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1149 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 335 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2006 | 146 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2016 | 3007 | 0.060 |
Why?
|
| Plaque, Amyloid | 1 | 2004 | 63 | 0.060 |
Why?
|
| Mammillary Bodies | 1 | 2003 | 2 | 0.060 |
Why?
|
| Diencephalon | 1 | 2003 | 10 | 0.060 |
Why?
|
| Consensus | 1 | 2007 | 612 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 750 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 2851 | 0.050 |
Why?
|
| Ubiquitin | 1 | 2004 | 141 | 0.050 |
Why?
|
| Genetic Testing | 4 | 2010 | 997 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 696 | 0.050 |
Why?
|
| Age Factors | 3 | 2018 | 2801 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2002 | 74 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 435 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2002 | 141 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2004 | 432 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 748 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 1172 | 0.050 |
Why?
|
| Synucleins | 3 | 2005 | 13 | 0.050 |
Why?
|
| Neurons | 2 | 2008 | 1927 | 0.040 |
Why?
|
| Genotype | 3 | 2010 | 2548 | 0.040 |
Why?
|
| International Cooperation | 2 | 2011 | 160 | 0.040 |
Why?
|
| Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2 | 2010 | 19 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 278 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 426 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2004 | 1588 | 0.040 |
Why?
|
| Risk Factors | 4 | 2015 | 10000 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2019 | 117 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2019 | 126 | 0.040 |
Why?
|
| Community Mental Health Services | 1 | 2019 | 38 | 0.040 |
Why?
|
| Adolescent | 4 | 2020 | 19087 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2020 | 369 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2010 | 715 | 0.040 |
Why?
|
| Cognition | 2 | 2015 | 735 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 153 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 322 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 333 | 0.040 |
Why?
|
| Disease Progression | 2 | 2014 | 2024 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2024 | 0.030 |
Why?
|
| Telephone | 1 | 2015 | 109 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 63 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 514 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2015 | 190 | 0.030 |
Why?
|
| Touch | 1 | 2014 | 34 | 0.030 |
Why?
|
| Pain | 1 | 2017 | 470 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 160 | 0.030 |
Why?
|
| Functional Laterality | 1 | 2014 | 181 | 0.030 |
Why?
|
| Posture | 1 | 2014 | 153 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2015 | 449 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3260 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 753 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3518 | 0.030 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 20 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2013 | 204 | 0.020 |
Why?
|
| Carbidopa | 1 | 2011 | 18 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 527 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1315 | 0.020 |
Why?
|
| Sensation | 1 | 2011 | 58 | 0.020 |
Why?
|
| Levodopa | 1 | 2011 | 89 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Brain | 3 | 2010 | 2947 | 0.020 |
Why?
|
| Syndrome | 1 | 2013 | 1114 | 0.020 |
Why?
|
| Jews | 1 | 2010 | 32 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1257 | 0.020 |
Why?
|
| Decision Making | 1 | 2015 | 650 | 0.020 |
Why?
|
| Executive Function | 1 | 2010 | 104 | 0.020 |
Why?
|
| Visual Perception | 1 | 2010 | 125 | 0.020 |
Why?
|
| Attention | 1 | 2010 | 194 | 0.020 |
Why?
|
| Telemedicine | 1 | 2015 | 426 | 0.020 |
Why?
|
| Cell Line | 2 | 2005 | 2776 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 280 | 0.020 |
Why?
|
| Physicians | 1 | 2015 | 584 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 773 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 169 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 793 | 0.020 |
Why?
|
| Hospitals | 1 | 2011 | 397 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1240 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 71 | 0.020 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2007 | 13 | 0.020 |
Why?
|
| Memory | 1 | 2010 | 360 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2011 | 806 | 0.020 |
Why?
|
| Publishing | 1 | 2007 | 108 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 1306 | 0.020 |
Why?
|
| Lewy Bodies | 1 | 2004 | 11 | 0.020 |
Why?
|
| Formates | 1 | 2004 | 13 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1799 | 0.020 |
Why?
|
| Epitope Mapping | 1 | 2005 | 78 | 0.010 |
Why?
|
| MPTP Poisoning | 1 | 2004 | 2 | 0.010 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 23 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 661 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 39 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2108 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 409 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 1390 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 185 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 326 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2004 | 160 | 0.010 |
Why?
|
| Cell Death | 1 | 2004 | 242 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1480 | 0.010 |
Why?
|
| tau Proteins | 1 | 2004 | 189 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 795 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2010 | 15981 | 0.010 |
Why?
|
| Transfection | 1 | 2004 | 1068 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 554 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1684 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6028 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 1390 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2002 | 157 | 0.010 |
Why?
|
| Prognosis | 1 | 2009 | 4508 | 0.010 |
Why?
|
| Animals | 3 | 2007 | 33728 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 2391 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3049 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 1021 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 17486 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2004 | 3716 | 0.010 |
Why?
|